Search
Beam Therapeutics Inc
BEAMAdd to Watchlist
24.215USD
-0.285-1.16%
Market hours 10/05, 09:55（ET）
2.49BMarket Cap
LossP/E TTM
Beam Therapeutics Inc (BEAM) Stock Price Target & Forecast
Analyst Rating
Based on 16 analysts giving stock ratings to Beam Therapeutics Inc in the past month.
Buy
6 Strong Buy
8 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
50.880USD+107.67%
BEAM Analyst Recommendation Trends
In the current month, BEAM has received 8 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BEAM average Analyst price target in the last month is 50.880.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
6
6
7
9
9
9
9
9
8
8
8
8
8
8
8
8
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16
16
17
19
19
19
19
19
BEAM Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, BEAM EPS is projected to reach -1.155 in FY2026Q3, following reported EPS of -1.176 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.99
-1.10
-1.11
-1.16
-1.18
Actual
2.37
-0.91
-1.18
--
--
Surprise
+339.36%
+16.63%
-6.28%
--
--
FAQs
What is Beam Therapeutics Inc's expected revenue for the next quarter?
Beam Therapeutics Inc's expected revenue is 8.75M.
What is Beam Therapeutics Inc's price target?
Analysts forecast that Beam Therapeutics Inc's price target is USD 50.88, with the highest forecast at USD 80.00 and the lowest forecast at USD 26.00.
How have Beam Therapeutics IncBEAM's recent earnings per share performed?
The market expectation was USD -1.18, while Beam Therapeutics IncBEAM's earnings per share (EPS) for the previous quarter was USD -0.91. EPS for the next quarter is expected at USD -1.16.
What is the analyst rating for Beam Therapeutics Inc?
Based on the ratings of Beam Therapeutics Inc's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.